HIGHLIGHTS
- who: Kunrui Zhu and colleagues from the Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China have published the paper: PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer, in the Journal: Cells 2022, 11, x FOR PEER REVIEW Cells 2022, 11, x FOR PEER REVIEW of /2022/
- what: Abnormal activation of the PAM pathway is one of the important reasons of endocrine resistance , which can be overcome or reversed by targeting pathways' components which activated during acquired drug resistance . This trial showed that alpelisib plus fulvestrant demonstrated better overall efficacy compared with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.